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The Biosciences Building
Professor Philip Rudland and Dr Roger 
Barraclough undertake much of their work 
in the Biosciences Building at the University 
of Liverpool. It is a unique location, that 
houses all the major equipment for biological 
research, including: 
•  Mass spectrometer-based proteomic facilities 
for protein identification (Professor R Beynon)
•  High throughput gene sequencing and analysis 
in the MRC Centre for Genomic Research 
(Professor N Hall)
•  Nuclear Magnetic Resonance for 
determination of atomic structures (Professor 
L-Y Lian and Dr I Barsukov)
•  Bioinformatics for structure-based drug design 
(Dr D Rigden)
•  Confocal cell imaging for observing the 
expression of genes in living cells (Dr D Bennett)
•  Animal and Drosophila facilities for housing 
our rat and recombinant fly models of 
metastasis, respectively (Mr E Birnie and Dr D 
Bennett)
Pioneering cancer researchers Professor Philip Rudland and Dr Roger Barraclough 
share insights into their latest work towards combating metastatic cancer, and discuss 
the people and institutions they collaborate with in the pursuit of this goal
Your main research endeavour is the 
discovery of genes and proteins that 
induce the most life-threatening aspect of 
cancer: metastasis. How did your scientific 
backgrounds lead you to this interest?
PR: I completed my PhD on the mechanism of 
initiation of protein synthesis at the Medical 
Research Council (MRC) Centre, Cambridge, in 
1970 under the supervision of FHC Crick and S 
Brenner, and went on to co-discover fibroblast 
growth factors (FGFs) in the early 1970s. I then 
joined the Imperial Cancer Research Fund and 
used FGFs to isolate the first breast stem cell 
line. Before joining the University of Liverpool 
as Professor of Biochemistry in 1986, I headed 
the Department of Cell and Molecular Biology 
at the Ludwig Institute for Cancer Research 
in Surrey, where I was successful in isolating 
human and rodent versions of benign and 
malignant breast cell lines. 
RB: I completed my PhD on nuclear protein 
phosphorylation in 1973. Three years later, I 
received a postdoctoral research fellowship at 
the University of Warwick, where I discovered 
the chloroplast protein chaperone. I joined the 
Ludwig Institute for Cancer Research in 1979. 
Since 1987 I have been Lecturer, Senior Lecturer 
and Reader at the University of Liverpool.
Your group has identified four novel 
metastasis-inducing proteins (MIPs). What 
is the importance of these MIPs and how 
do they relate to findings from your current 
research endeavours?
PR & RB: The importance of the discovery of 
the MIPs was that it was the first time that 
proteins inducing the life-threatening aspect 
of cancer were identified systematically. The 
present programme has identified several 
of these MIPs as being useful for predicting 
patients who are liable to die prematurely 
from metastatic breast cancer. Therefore, 
these at risk patients can be treated 
extensively with current chemotherapies 
and other patients can be spared from the 
debilitating side effects of such treatments. 
Another MIP, which appears in the early 
premalignant stages of breast cancer, may be 
utilised as a diagnostic marker in blood for 
ovarian cancer.
You have backed up your investigations with 
more than 20 years of research, including an 
array of groundbreaking pilot studies funded 
by the Cancer and Polio Research Fund 
(CPRF). Speaking generally, is there enough 
support for early-stage research?
PR & RB: Unfortunately, in the UK, there is 
very little research money available for pilot 
studies. We have been particularly fortunate 
in that the CPRF has enabled us to conduct 
pilot studies into fresh areas on a long-term, 
five-year basis. Their support has given us 
the chance to operate from the start in a 
virgin territory such as metastasis, which the 
standard governmental agencies and major 
cancer charities have been 
reluctant to fund at a basic 
scientific level in the past.
Are you collaborating with other 
laboratories in the course of 
your investigations? 
PR & RB: We conduct collaborations with 
many other laboratories. In Liverpool, for 
example, high throughput, massively parallel 
DNA sequencing has been undertaken with 
Professor R Sibson of the Centre for Genomic 
Research and the Beijing Genomics Institute, 
Hong Kong, to identify mutations in the 
DNA within and surrounding our MIPs in 
breast cancer cell lines.  Additionally, former 
postdoc Professor Y Ke discovered a prostate 
cancer MIP, which is hypothesised to work by 
stimulating the production of factors for new 
blood vessels. Outside Liverpool, another new 
MIP has been discovered by Dr M El-Tanani, 
who is also a former postdoc and now at 
Queen’s University Belfast.  
Work on our existing MIPs continues with 
Dr S Gross in Aston University, Birmingham, 
using an automated system to measure 
cell migration. It also continues with Dr N J 
Jones here at the University of Liverpool and 
Dr B Davies at Astra Zeneca, Manchester, 
in attempting to block the remaining 
(nonhomologous) double strand DNA 
repair process in order to destroy the cancer 
cell selectively. External collaborations 
are now starting to support our model for 
the MIPs and suggest that our MIPs are 
multifunctional proteins with more than one 
target in a cell.
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Putting secondary cancer first
Researchers at the University of Liverpool, supported by the Cancer and Polio Research Fund, have been making 
inroads in the fight against metastatic cancer, beginning with the identification of the proteins responsible
PRIMARY CANCER IS a nightmare diagnosis 
no patient hopes to receive from a doctor. 
The truth is that primary tumours themselves 
rarely kill people, as they can be removed with 
surgery.  However, many of these primary 
cancer patients can become secondary cancer 
patients, if their cancer metastasises. 
With secondary cancer, metastatic cancer 
cells break off from the original tumour mass 
and travel through the blood and lymphatic 
systems to colonise new parts of the body. 
Therefore, though the primary tumour has 
long ago been removed, its progeny can 
return to wreak havoc in another organ. 
Diagnosing these secondary, metastatic 
tumours is difficult. It currently calls for the 
use of imaging processes – which generally 
catch them too late – or the identification 
of cancer cells in the lymph nodes, which is 
unreliable. Neither method is a significant 
help to individual patients, as the timescale 
over which secondary tumours appear can 
be unpredictable, meaning that too often the 
disease gains the element of surprise even 
after its first strike.
THE TROUBLE WITH TREATMENT
Current treatment strategies are not 
much more effective than their diagnostic 
counterparts. Secondary cancer is often able 
to spread to numerous sites within the body 
before it is apprehended, at which point the 
surgical intervention, though so effective 
for the primary tumour, is no longer viable. 
Doctors are then forced to treat patients with 
cytotoxic chemicals, and these chemicals 
damage the rapidly multiplying cancer 
cells in addition to many other native cells. 
Chemotherapy is limited by its propensity for 
harming necessary bodily cells with ‘friendly 
fire’. Therefore, it cannot kill the secondary 
cancer outright – severely limiting the healing 
capacity of current approaches. In the UK, 
the Cancer and Polio Research Fund (CPRF) 
was one of the first charities to recognise the 
danger secondary cancer poses, vowing to 
end its threat. To this end, the organisation 
has funded research into metastasis over the 
last 20 years. 
Among the researchers undertaking these 
important projects are Professor Philip 
Rudland and Dr Roger Barraclough from the 
University of Liverpool, and their research is 
proving extremely promising for meeting the 
CPRF’s secondary cancer-ending goal. In the 
early 1990s, Rudland and Barraclough were the 
first to discover metastasis-inducing proteins 
(MIPs), a group of proteins responsible for 
this most lethal form of cancer. The pair also 
identified the first four proteins to join the 
group: S100A4, S100P, osteopontin and AGR2. 
Since then, they have worked with a large pool 
of collaborators to help stop metastasis in its 
tracks – producing some highly interesting 
results in the process.
MIPS AND RAT MODELS
Identifying the first four MIPs was an 
important step towards improving treatment 
for cancer patients, as they have been shown 
to be strongly associated with early patient 
death from metastasis. 
Rudland and Barraclough had to overcome 
many hurdles over many years of research 
in order to discover these MIPs. The major 
obstacle was developing a suitable stem cell 
line that could be manipulated in a cell culture 
in vitro and that would produce benign tumours 
that failed to metastasise when introduced 
into non-immunosuppressed animals. Though 
it took scientific investigations which spanned 
three decades, Rudland and Barraclough met 
this challenge. They produced a stem cell line 
from a benign rat breast tumour growing in 
an inbred colony of rats that only produced 
benign, non-metastasising tumours when 
reinserted into non-immunosuppressed rats. 
After a further 10 years of research, they 
isolated benign and malignant breast tumour 
cell lines in humans, testing the differentially 
expressed genes by inserting them into their 
unique benign nonmetastatic breast cell 
line. When proteins from these genes cause 
metastasis in their complete animal model, 
Rudland and Barraclough know that they have 
discovered another MIP – as well as a potential 
target for fighting cancer. In fact, through this 
streamlined pathway to discovering more 
MIPs, the scientists have confirmed two further 
candidates with several possibilities still open.
Although a number of potential MIPs had 
already been linked with metastasis before 
this study, it was only by using their unique 
stem cell line in intact rats that the researchers 
were able to prove that certain proteins could 
directly induce metastasis. Moreover, the MIPs 
confirmed using this assay were of a different 
class to those responsible for inducing the 
primary tumours. Alone, they could not 
induce the development of a primary tumour; 
they could only work in concert with existing 
oncogenes to induce metastasis. 
CREATING CANCER CURES
The current research programme of the 
CPRF Group at the University of Liverpool 
is focusing on two main points. First, the 
team is developing predictive tools to 
identify individuals likely to suffer from 
metastatic disease. Second, the researchers 
are helping to create therapies for eradicating 
metastatic cells.
Accordingly, Rudland and Barraclough are 
currently utilising a wide array of investigative 
approaches to advance the present 
understanding of MIPs and their workings. 
The Biosciences Building where the team is 
based allows for access to Nuclear Magnetic 
Resonance equipment, which has facilitated 
the characterisation of the atomic structure of 
AGR2, and the structure of S100A4’s interaction 
with a cytoskeletal protein. Simultaneously, 
it places the researchers in a perfect position 
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Benign tumour cells growing in culture; A metastasis in 
the rat stained for MIP AGR2; Antibody staining for MIP 
S100P in human breast cancer; Antibody staining for MIP 
S100A4 in human breast cancer; 3D structure of AGR2 
dimer; 3D structure of S100P dimer.
to collaborate with scientists in other fields, 
for example, to map the effects of MIPs in 
transgenic flies with Dr D Bennett, allowing them 
to gauge the downstream pathways induced by 
these proteins and to test inhibitors directly by 
introducing them into developing larvae.
FURTHER DISCOVERIES
The more recent discoveries of the Liverpool 
group have fallen into two categories: clinical 
and molecular. On the molecular level with 
Dr N Jones, the researchers have been able 
to determine that the probable cause of MIP 
overexpression is failure of the homologous 
double-strand DNA repair mechanism, which 
destabilises the cancer genome and promotes 
the selection of metastatic cells. Two of the 
intracellular MIPs under study have been found 
to stimulate cell migration and invasion by 
binding to parts of the cytoskeleton, while two 
of their extracellular cousins, it has emerged, 
stimulate cell adhesion to extracellular 
material, enhancing the cell’s ability to survive 
without the tumour’s protection. 
Perhaps the most important clinical finding 
has been the simple demonstration that when 
MIPs are overproduced, patients die more 
quickly. Using tissue specimens collected 
by cancer tissue banks such as the Liverpool 
Tissue Bank, which was originally set up in 
part by Rudland, the cancer researchers have 
been using immunohistochemical staining to 
identify MIPs and correlate their presence with 
patient outcome. Rudland and Barraclough’s 
goal for this process is to reveal more about 
the diagnostic potential of MIPs, and although 
the MIPs may take many years to study 
comprehensively, it seems likely that such 
studies will be well worth the wait.
DISCOVERY AND USE OF METASTASIS-
INDUCING PROTEINS IN DIAGNOSIS 
AND TREATMENT OF BREAST AND 
OTHER CANCERS
OBJECTIVES
To help doctors identify patients most at risk of 
dying from cancer and to develop more effective 
drugs to combat metastatic disease.
KEY COLLABORATORS
Professor David Fernig; Professor Rob 
Beynon; Professor Neil Hall; Professor 
Lu-Yun Lian; Dr Igor Barsukov, Institute of 
Integrative Biology, University of Liverpool, UK • 
Dr Andrew Carnell, Department of Chemistry, 
University of Liverpool, UK • Professor 
Terry Jones; Dr Daniel Crooks; Mr Michael 
Jenkinson, Fazakerley Hospital, UK • Professor 
Chris Foster; Dr Nitin Khirwadkar; Professor 
Christopher Holcombe; Mr John Winstanley, 
Royal Liverpool University Hospital, UK • 
Professor Ross Sibson, CRUK Centre for Cancer 
Research/Beijing Genomics Institute, Hong Kong 
• Professor Sarah Coupland, Liverpool Tissue 
Bank, UK • Dr Carol Walker, Walton Brain 
Tissue Bank, UK • Dr Stephane Gross, Aston 
University, UK• Dr Mohamed El-Tanani, Queens 
University, Belfast, UK • Dr Barry Davies, 
AstraZeneca, UK
PARTNERS
Cancer and Polio Research Fund (CPRF)
FUNDING (PRESENT)
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PHILIP RUDLAND is currently Professor of 
Biochemistry at the University of Liverpool 
where he co-discovered the metastasis inducing 
proteins (MIPs), S100A4, osteopontin, S100P 
and AGR2.  
 
ROGER BARRACLOUGH joined the University 
of Liverpool where he co-discovered MIPs 
and worked with Rudland to discover the 
mechanisms of their regulation and activity in 
relation to their metastasis-inducing properties.
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